Hacken ET, Valentin R, Regis FFD, et al. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018;3(19). doi:10.1172/jci.insight.121438.

Bellmunt J, Lalani A-KA, Jacobus S, et al. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer. 2018;119(6):707-712. doi:10.1038/s41416-018-0261-0.

Joung J, Engreitz JM, Konermann S, et al. Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood. Nature. 2017;548(7667):343-346. doi:10.1038/nature23451.

Iniguez AB, Alexe G, Wang EJ, et al. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell. 2018;34(6):922-938.e7. doi:10.1016/j.ccell.2018.11.005.

Posfai D, Eubanks AL, Keim AI, et al. Identification of Hsp90 Inhibitors with Anti-Plasmodium Activity. Antimicrob Agents Chemother. 2018;62(4). doi:10.1128/AAC.01799-17.

Edelman G, Rodon J, Lager J, et al. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. Oncologist. 2018;23(4):401-e38. doi:10.1634/theoncologist.2017-0691.

Lopez-Sambrooks C, Shrimal S, Khodier C, et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nat Chem Biol. 2016;12(12):1023-1030. doi:10.1038/nchembio.2194.

Dickinson BC, Packer MS, Badran AH, Liu DR. A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations. Nat Commun. 2014;5:5352. doi:10.1038/ncomms6352.

Martyn DC, Cortese JF, Tyndall E, et al. Antiplasmodial activity of piperazine sulfonamides. Bioorg Med Chem Lett. 2010;20(1):218-21. doi:10.1016/j.bmcl.2009.10.130.

Sakurai K, Snyder TM, Liu DR. DNA-templated functional group transformations enable sequence-programmed synthesis using small-molecule reagents. J Am Chem Soc. 2005;127(6):1660-1. doi:10.1021/ja0432315.